Oppenheimer's top 50 small- and mid-cap Sell ideas
at seekingalpha.com (Tue, 27-Oct 8:47 AM)
NKTR spotlights rezpegaldesleukin durability: 63% of alopecia areata responders maintained SALT=20 six months after stopping treatment
Market Chameleon (Thu, 1-Oct 7:59 AM)
Rezpegaldesleukin Sets New Standard in Atopic Dermatitis After Meeting All Primary and Key Secondary Endpoints in Phase 2b Study
Market Chameleon (Tue, 25-Aug 9:16 AM)
Nektar Therapeutics to Announce Q2 Results on August 13—Upcoming Earnings Call Brings Pipeline Focus Into Spotlight
Market Chameleon (Wed, 29-Jul 9:30 AM)
